VIP and cancer: Furthermore, overexpression of VIP may represent a biomarker useful to identify patients with PDAC and other cancers sensitive to the ICB activity of VIP-R antagonists (Fig. 1b, e), analogous to the use of PD-L1 staining of cancer as a predictive biomarker for response to anti-PD1 ICB.